All In Biotech

Drug Trial Radar · NCT04233190

A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

A Randomized, Parallel-Group, Open, Two-Period, Comparative Non-Inferiority Study of Eurofarma's Formoterol/Budesonide vs Alenia in the Treatment of Moderate to Severe Persistent Asthma With and Without Chronic Obstructive Pulmonary COPD

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 472 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

472

Actual

Start

Apr 19, 2023

Primary completion

Oct 28, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary disease (COPD). ⚠️study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Conditions

  • Asthma Copd

Interventions

  • Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcgDrug

    one inhalation, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eurofarma Laboratorios S.A

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.